Professor of Medicine, Indiana University
Hematology
Dr. George W. Sledge Jr., MD
|
|
Give Review
George Sledge is an expert in the field of Hematology. He attended St Louis University School of Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". George Sledge is a published doctor and has 100 publications published. The lastest was: 'Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.' George Sledge is registered with Medicare and accepts Medicare payments.
Publications
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
- The future of breast Cancer systemic therapy: the next 10 years.
- Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast Cancer cell lines.
- Decade in review-targeted therapy: Successes, toxicities and challenges in solid tumours.
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
- Comparison of younger and older breast Cancer survivors and age-matched controls on specific and overall quality of life domains.
- Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast Cancer participating in E5103.
- Characterizing the heterogeneity of triple-negative breast Cancers using microdissected normal ductal epithelium and RNA-sequencing.
- Development and psychometric testing of a breast Cancer survivor self-efficacy scale.
- Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity.
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast Cancer in the North Cent...
- ASCO's Approach to a Learning Health Care System in Oncology.
- A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the Breast.
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and Cancer.
- Small-molecule inhibition of the uPAR·uPA interaction: Synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast Cancer metastasis.
- Establishment and characterization of a novel cell line derived from human thymoma AB tumor.
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast Cancer xenograft models.
- ASCO 2012: A Good Year for HER2 Therapy.
- Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer.
- Predicting fear of breast Cancer recurrence and self-efficacy in survivors by age at diagnosis.
- Synthesis of 2-[11C]methoxy-3,17β-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in Cancers.
- Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial.
- The Challenge and Promise of the Genomic Era.
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
- Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast Cancer patients.
- Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block Cancer cell invasion.
- Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metasta...
- Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide.
- Anti-Vascular Endothelial Growth Factor Therapy for Breast Cancer: Can We Pick the Winners?
- Radiosynthesis of [(11)C]Vandetanib and [(11)C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in Cancer.
- Rethinking the metastatic cascade as a therapeutic target.
- HER2011: the changing face of HER2-positive breast Cancer.
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast Cancer from the north central Cancer treatment group N9831 adjuvant trastuzu...
- Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast Cancer.
- Heading in a new direction: drug permeability in breast Cancer brain metastasis.
- Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast Cancer.
- Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in Cancer.
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
- Targeted therapies in early-stage breast Cancer: achievements and promises.
- Ten remarkable years.
- Where to with HER2?
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
- Screening for breast Cancer: is the picture changing?
- Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expres...
- What's PARPing up for triple-negative breast Cancer?
- Loving our bones.
- A phase II study of oral enzastaurin in patients with metastatic breast Cancer previously treated with an anthracycline and a taxane containing regimen.
- Innumerable variations: combining biologics.
- Triple-negative breast Cancer: risk factors to potential targets.
- The rapid evolution of breast Cancer therapeutic agents.
- Memorandum to the President-Elect: a breast Cancer agenda.
- A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast Cancer.
- How long?
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast Cancer compared with classical clinicopathologic features.
- Diffusion of new technologies in breast Cancer: do guidelines matter?
- Breast Cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.
- Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast Cancer.
- Random thoughts on chemotherapy.
- Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription po...
- The new millennium for adjuvant therapy in breast Cancer.
- Weekly paclitaxel in the adjuvant treatment of breast Cancer.
- Pill-popping and therapeutic outcome.
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuva...
- Advances in HER2-positive breast Cancer.
- PDGF BB induces VEGF secretion in ovarian Cancer.
- Diagnostic dilemmas in breast Cancer.
- Preoperative therapy for breast Cancer.
- Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast Cancer: final analysis from INT-0137 (S9313).
- Evidence-based medicine in breast Cancer.
- Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastat...
- 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast Cancer cells.
- p27(Kip1) and cyclin E expression and breast Cancer survival after treatment with adjuvant chemotherapy.
- The system of the world.
- Circulating tumor cells in breast Cancer: blood will tell.
- The era of radical incrementalism?
- Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate Cancer model.
- The role of angiogenesis inhibition in the treatment of breast Cancer.
- Bioregulatory niches in breast Cancer.
- Protein kinase C-beta as a therapeutic target in breast Cancer.
- Hormonal therapy: still much to learn.
- Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast Cancer.
- Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast Cancer.
- A physiologic imaging pilot study of breast Cancer treated with AZD2171.
- Twenty years of systemic therapy for breast Cancer.
- beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 Cancer cells.
- VEGF-targeting therapy for breast Cancer.
- Transforming technologies and breast Cancer.
- New developments in adjuvant therapy for breast Cancer.
- A new age now begins.
- What is targeted therapy?
- Preoperative therapy comes of age.
- On not being the "hostess with the mostest".
- HERe-2 stay: the continuing importance of translational research in breast Cancer.
- Breast Cancer as a world challenge.
Schools
Tulane University School Of Medicine
Saint Louis University
University Tex San Antonio
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Health Science Center -
St Louis University School of Medicine -
Tulane University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Rebecca W. Silbermann, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danielle M. Doyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna Maria V. Storniolo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence H. Einhorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Dugan Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lida A. Mina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Carr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Walgren, MD |
|
|
Dr. Sead Beganovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose M. Azar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmad A. Al-Hader, MD |